CRANBERRY TOWNSHIP, Pa., Sept. 17 /CNW/ -- Three Rivers Pharmaceuticals,
LLC announced today that it has signed a definitive license agreement with
Amgen Inc. to expand its commercial rights to the hepatitis C drug Infergen.
Three Rivers Pharmaceuticals will obtain commercial rights to Infergen in all
markets except Japan. In addition, Three Rivers Pharmaceuticals will obtain
commercial rights to China effective March 31, 2009. Three Rivers
Pharmaceuticals currently has commercial rights to Infergen in the United
States and Canada.
"The expansion of commercial rights to Infergen compliments Three Rivers
Pharmaceuticals strategy to continue to grow its hepatitis C franchise,"
stated Patrick Kerrish RPh., MBA Three Rivers Pharmaceuticals' Executive Vice
President of Business Development.
Three Rivers Pharmaceuticals will seek marketing partners to assist with
the commercialization of Infergen outside of the United States. Interested
marketing partners should contact Patrick Kerrish at
Infergen, or consensus interferon, is a unique, bio-optimized, selective
and highly potent type 1 interferon alpha originally developed by Amgen and
launched in the United States in 1997. Infergen is indicated for the
treatment of chronic HCV infection in patients 18 years of age or older with
compensated liver disease who have anti-HCV serum antibodies and /or the
presence of HCV RNA.
Important Safety Information
Physicians and patients can obtain additional prescribing information
regarding Infergen, including the product's safety profile and the box warning
for all interferon alphas regarding neuropsychiatric, autoimmune, ischemic and
infectious disorders, by visiting www.infergen.com .
About Three Rivers Pharmaceuticals
Three Rivers Pharmaceuticals is a privately held company headquartered in
Cranberry Township, Pennsylvania that focuses on specialized therapies
including hepatitis C therapies. With its unique experience and understanding
of the complex challenges of treating chronic, difficult diseases, Three
Rivers is a valuable partner in the healthcare community.
The company's mission is to develop, manufacture, and market the highest
quality branded and generic drug products for patients with serious diseases.
Three Rivers Pharmaceuticals focuses on the specialized therapies because of
its extensive knowledge and experience in this area. More information about
the company can be found at www.3riverspharma.com .
For further information:
For further information: Patrick Kerrish of Three Rivers
Pharmaceuticals, +1-724-778-6013, email@example.com Web Site: